Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences Inc (ACHV)
NASDAQ:ACHV
Achieve Life Sciences (ACHV) Stock Price & Analysis
1,042 Followers
ACHV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.03 - $8.37
Previous Close$5.21
Volume156.65K
Average Volume (3M)118.44K
Market Cap
$174.11M
Enterprise Value$180.10M
Total Cash (Recent Filing)$15.55M
Total Debt (Recent Filing)$16.73M
Price to Earnings (P/E)-4.0
Beta1.29
Next Earnings
Aug 08, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding34,341,303
10 Day Avg. Volume138,502
30 Day Avg. Volume118,435
Standard Deviation0.26
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)3.64
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.74
Forecast
1Y Price Target
$16.40Price Target Upside223.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Achieve Life Sciences News
Bulls Say, Bears Say
Bulls Say
Financial StabilityAchieve reported strengthened balance sheet through financing which should extend cash runway into 2026.
Market OpportunitySignificant opportunity for a branded drug to take market share in the smoking cessation market.
Regulatory ProgressFDA alignment was secured for the next steps required for submitting an NDA for cytisinicline.
Bears Say
Clinical Trial RequirementsThe agency is seeking extensive safety data, requiring over 300 and 100 patients for six- and twelve-month studies, respectively, which could delay the drug's development.
Financial ImpactDue to anticipated delays in cytisinicline's approval and launch, the price target for the company has been revised downwards from $35 to $25.
Regulatory ConcernsFDA insists on a longer-term exposure study to further validate the safety profile of cytisinicline, potentially impacting approval timelines.
---
Ownership Overview
12.86% Insiders
2.31% Mutual Funds
27.69% Other Institutional Investors
57.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACHV FAQ
What was Achieve Life Sciences Inc’s price range in the past 12 months?
Achieve Life Sciences Inc lowest stock price was $3.03 and its highest was $8.37 in the past 12 months.
What is Achieve Life Sciences Inc’s market cap?
Currently, no data Available
When is Achieve Life Sciences Inc’s upcoming earnings report date?
Achieve Life Sciences Inc’s upcoming earnings report date is Aug 08, 2024 which is in 83 days.
How were Achieve Life Sciences Inc’s earnings last quarter?
Achieve Life Sciences Inc released its earnings results on May 09, 2024. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.242 by -$0.018.
Is Achieve Life Sciences Inc overvalued?
According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued.
Does Achieve Life Sciences Inc pay dividends?
Achieve Life Sciences Inc does not currently pay dividends.
What is Achieve Life Sciences Inc’s EPS estimate?
Achieve Life Sciences Inc’s EPS estimate is -$0.24.
How many shares outstanding does Achieve Life Sciences Inc have?
Achieve Life Sciences Inc has 34,341,305 shares outstanding.
What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?
Achieve Life Sciences Inc reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.242. Following the earnings report the stock price went up 1.766%.
Which hedge fund is a major shareholder of Achieve Life Sciences Inc?
Currently, no hedge funds are holding shares in ACHV
---
Achieve Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.40 (223.47% Upside)
$16.40 (223.47% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $91.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.7%
Last 30 Days ▲ 10.5%
Last 30 Days ▲ 10.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.82%
12-Months-Change
Fundamentals
Return on Equity
-109.49%
Trailing 12-Months
Asset Growth
236.71%
Trailing 12-Months
Company Description
Achieve Life Sciences Inc
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
---
ACHV Earnings Call
Q1 2024
0:00 / 0:00
---
ACHV Stock 12 Month Forecast
Average Price Target
$16.40
▲(223.47% Upside)
Technical Analysis
Best Analysts Covering ACHV
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+14.68%
reiterated a buy rating 4 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +14.68% per trade.
---